首页> 外文期刊>Artificial Organs >Pediatric patients requiring extracorporeal membrane oxygenation in heart failure: 30‐day outcomes; mid‐ and long‐term survival. A single center experience
【24h】

Pediatric patients requiring extracorporeal membrane oxygenation in heart failure: 30‐day outcomes; mid‐ and long‐term survival. A single center experience

机译:在心力衰竭中需要体外膜氧合的儿科患者:30天的结果; 中期和长期生存。 单一中心体验

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Nowadays, an increasing number of neonatal and pediatric patients with severe heart failure benefits from extracorporeal membrane oxygenation (ECMO) support. A total of 39 pediatric patients needed venoarterial ECMO (vaECMO) support in our department between January 2008 and December 2016. Patients were retrospectively divided in two groups: 30‐day survivor group (17 patients) and 30‐day nonsurvivor group (22 patients). Outcome and factors predictive for 30‐day mortality and mid‐ as well as long‐term survival up to 7‐year follow‐up were analyzed by univariate analysis and Kaplan‐Meier survival estimation. Basic demographics and preoperative characteristics did not differ between groups ( P 0.05). 67% of patients were successfully weaned off ECMO and 44% survived 30‐day after ECMO application. After 7‐year follow‐up 28% of pediatric patients were alive. Thirty‐day survivors were significantly more likely to undergo elective cardiac surgery ( P = 0.001), whereas significantly more 30‐day nonsurvivors underwent urgent surgery ( P = 0.004). Odds of incidence of catecholamine refractory circulatory failure, failed myocardial recovery, and cerebral edema was significantly higher in 30‐day nonsurvivor group (41.6‐fold, 16‐fold, and 2.5‐fold, respectively). Kaplan‐Meier survival estimation analysis revealed significant differences in terms of mid‐ and long‐term survival among neonates, infants, toddlers, and preadolescents (Breslow P = 0.037 and Log‐Rank P = 0.028, respectively). vaECMO provides an efficient therapy option for life‐threatening heart disorders in neonates and pediatric patients being at high risk for myocardial failure leading to circulatory arrest. Urgency of surgery effected on higher mortality, but there was no difference in terms of mortality in 30‐day survivor group in comparison to 30‐day nonsurvivor group among neonates, infants, toddlers, and preadolescents.
机译:摘要如今,越来越多的新生儿和儿科患者免受体外膜氧合(ECMO)载体的严重心力衰竭益处。 39名儿科患者在2008年1月至2016年12月期间,我们部门需要veroarterial ECMO(VAECMO)支持。患者分别分为两组:30天幸存群(17名患者)和30天的Nonsurvivor组(22名患者) 。通过单变量分析和Kaplan-Meier生存期估算,分析了预测30天死亡率和长期存活率的结果和因素,高达7年的随访。基本的人口统计学和术前特征在组之间没有差异(P> 0.05)。 67%的患者成功地断绝了ECMO,44%在ECMO应用后30天存活。 7年后的后续后续28%的儿科患者还活着。 30天的幸存者更容易接受选修心脏手术(p = 0.001),而明显更多的30天的非尿动率接受紧急手术(p = 0.004)。 30天的非尿道组(分别分别为41.6倍,16倍和2.5倍),儿科耐火性循环衰竭,心肌回收率失败和脑水肿的发生率显着高。 Kaplan-Meier存活估算分析显示了新生儿,婴儿,幼儿和重叠者中长期存活方面的显着差异(分别是Brieslow P = 0.037和log-ange p = 0.028)。 VAECMO为新生儿和儿科患者的危及生命的心脏病患者提供了有效的治疗选择,患心肌失效的高风险导致循环逮捕。手术的紧急性对更高的死亡率进行了影响,但在30天的幸存者组中死亡率没有差异,与新生儿,婴儿,幼儿和腹股沟处的30天非尿道集团相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号